The shareholder letter is a routine update with no new material financial guidance, but the NYSE American listing notice is a concrete risk. Monitor the June 7 compliance plan deadline — failure to submit or gain acceptance could trigger delisting proceedings. The improved Q1 revenue and gross margin trajectory is positive, but the going-concern qualification and $14M market cap make the equity highly speculative.
Price Chart
Executive Summary
Picard Medical issued a shareholder letter from Chairman Richard Fang recapping 2025 results ($4.9M revenue, +12.5% YoY) and Q1 2026 performance ($1.2M revenue, +85% YoY; 24% gross margin vs. -58% a year ago). The letter also discloses that the company received NYSE American notices regarding stockholders' equity requirements and has until June 7, 2026 to submit a compliance plan. While operational metrics improved, the company remains unprofitable with a going-concern qualification and faces a near-term delisting risk.
Key Facts
- FY2025 total revenue $4.9M, up 12.5% YoY; product revenue $4.7M (96% of total)
- Q1 2026 revenue $1.2M, up 85% YoY; gross profit turned positive at 24% margin vs. -58% in Q1 2025
- IPO raised $17.4M net equity; additional $9.7M debt financing; year-end cash $11.5M vs. $0.1M at YE 2024
- Q1 2026: repaid ~$7.4M senior secured debt in cash, settled $2.1M through equity
- Post-Q1: raised $5.0M gross in public offering; entered warrant exchange eliminating ratchet provisions
- Auditors included a going-concern qualification in 2025 financial statements
- Received NYSE American notices regarding stockholders' equity; compliance plan due June 7, 2026
- Emperor TAH second-gen animal testing completed; seeking regulatory approval as early as 2028
- Pending FDA decision on PMA supplement to expand indications to bridge-to-candidacy patients
Financial Impact
Q1 2026 revenue $1.2M (85% YoY growth); gross margin improved to 24% from -58%; $5.0M post-quarter equity raise; $7.4M debt principal repaid in cash during Q1
Risk Factors
- NYSE American delisting risk if compliance plan not accepted by June 7, 2026
- Going-concern qualification in audited financials; company not yet profitable
- Regulatory uncertainty for Emperor TAH approval (target 2028) and pending PMA supplement
- Small market cap ($14M) and low liquidity amplify volatility
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001829126-26-005779 |
| Document: picardmedical_ex99-1.htm | 0001829126-26-005779 |
| Document: 0001829126-26-005779-index-headers.html | 0001829126-26-005779 |
| Document: 0001829126-26-005779-index.html | 0001829126-26-005779 |
| Document: 0001829126-26-005779.txt | 0001829126-26-005779 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | 8-K | $6.43 | awaiting T+60 | — | $6.83 (+6.22%) |
Oct 22, 2026 5d ago | S-3 | $7.37 | awaiting T+60 | — | $6.83 (+7.33%) |
Oct 6, 2026 21d ago | 8-K | $8.74 | awaiting T+60 | — | $6.83 (+21.85%) |
Jul 27, 2026 13w ago | 8-K | $0.0878 $0.2096 | ▲ +138.72% | ▲ +134.67% | $6.83 (+7679.04%) |
Jul 15, 2026 14w ago | DEFA14A | $0.1600 $0.1896 | ▲ +18.50% | ▲ +14.79% | $6.83 (+4168.75%) |
Jul 8, 2026 15w ago | DEFA14A | $0.1500 $0.0864 | ▼ −42.40% | ▼ −44.89% | $6.83 (+4453.33%) |
Jul 2, 2026 16w ago | 8-K / 425 | $0.1694 | awaiting T+60 | — | $6.83 (+3931.88%) |
Jun 29, 2026 17w ago | 8-K | $0.1559 $0.0910 | ▼ −41.63% | ▼ −45.25% | $6.83 (+4281.01%) |
Jun 2, 2026 21w ago | Press Release | $13.50 | awaiting T+60 | — | $6.83 (−49.41%) |
Jun 2, 2026 21w ago | 8-K | $13.50 | awaiting T+60 | — | $6.83 (+49.41%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers